290 related articles for article (PubMed ID: 25289928)
1. Role of osteocytes in multiple myeloma bone disease.
Delgado-Calle J; Bellido T; Roodman GD
Curr Opin Support Palliat Care; 2014 Dec; 8(4):407-13. PubMed ID: 25289928
[TBL] [Abstract][Full Text] [Related]
2. Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption.
Kitaura H; Marahleh A; Ohori F; Noguchi T; Shen WR; Qi J; Nara Y; Pramusita A; Kinjo R; Mizoguchi I
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708317
[TBL] [Abstract][Full Text] [Related]
3. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.
Liu H; He J; Bagheri-Yarmand R; Li Z; Liu R; Wang Z; Bach DH; Huang YH; Lin P; Guise TA; Gagel RF; Yang J
Nat Commun; 2022 Jun; 13(1):3684. PubMed ID: 35760800
[TBL] [Abstract][Full Text] [Related]
4. Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy.
Toscani D; Bolzoni M; Ferretti M; Palumbo C; Giuliani N
Front Immunol; 2018; 9():2467. PubMed ID: 30410490
[TBL] [Abstract][Full Text] [Related]
5. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
Delgado-Calle J; Anderson J; Cregor MD; Hiasa M; Chirgwin JM; Carlesso N; Yoneda T; Mohammad KS; Plotkin LI; Roodman GD; Bellido T
Cancer Res; 2016 Mar; 76(5):1089-100. PubMed ID: 26833121
[TBL] [Abstract][Full Text] [Related]
6. Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.
Giuliani N; Ferretti M; Bolzoni M; Storti P; Lazzaretti M; Dalla Palma B; Bonomini S; Martella E; Agnelli L; Neri A; Ceccarelli F; Palumbo C
Leukemia; 2012 Jun; 26(6):1391-401. PubMed ID: 22289923
[TBL] [Abstract][Full Text] [Related]
7. [Mechanisms of myeloma-induced bone disease].
Abe M
Clin Calcium; 2016 May; 26(5):699-706. PubMed ID: 27117615
[TBL] [Abstract][Full Text] [Related]
8. Osteocyte control of osteoclastogenesis.
O'Brien CA; Nakashima T; Takayanagi H
Bone; 2013 Jun; 54(2):258-63. PubMed ID: 22939943
[TBL] [Abstract][Full Text] [Related]
9. Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes.
Allison H; Holdsworth G; McNamara LM
BMC Mol Cell Biol; 2020 Nov; 21(1):78. PubMed ID: 33148174
[TBL] [Abstract][Full Text] [Related]
10. Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations.
Kennedy OD; Herman BC; Laudier DM; Majeska RJ; Sun HB; Schaffler MB
Bone; 2012 May; 50(5):1115-22. PubMed ID: 22342796
[TBL] [Abstract][Full Text] [Related]
11. Osteocyte-Mediated Translation of Mechanical Stimuli to Cellular Signaling and Its Role in Bone and Non-bone-Related Clinical Complications.
Yan Y; Wang L; Ge L; Pathak JL
Curr Osteoporos Rep; 2020 Feb; 18(1):67-80. PubMed ID: 31953640
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
13. Osteocytes and Paget's Disease of Bone.
Tenshin H; Delgado-Calle J; Windle JJ; Roodman GD; Chirgwin JM; Kurihara N
Curr Osteoporos Rep; 2024 Apr; 22(2):266-272. PubMed ID: 38457001
[TBL] [Abstract][Full Text] [Related]
14. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
15. Targeted disruption of BMP signaling through type IA receptor (BMPR1A) in osteocyte suppresses SOST and RANKL, leading to dramatic increase in bone mass, bone mineral density and mechanical strength.
Kamiya N; Shuxian L; Yamaguchi R; Phipps M; Aruwajoye O; Adapala NS; Yuan H; Kim HK; Feng JQ
Bone; 2016 Oct; 91():53-63. PubMed ID: 27402532
[TBL] [Abstract][Full Text] [Related]
16. Osteocyte-driven bone remodeling.
Bellido T
Calcif Tissue Int; 2014 Jan; 94(1):25-34. PubMed ID: 24002178
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
Wijenayaka AR; Kogawa M; Lim HP; Bonewald LF; Findlay DM; Atkins GJ
PLoS One; 2011; 6(10):e25900. PubMed ID: 21991382
[TBL] [Abstract][Full Text] [Related]
18. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis.
Kim HJ; Kim HJ; Choi Y; Bae MK; Hwang DS; Shin SH; Lee JY
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909508
[TBL] [Abstract][Full Text] [Related]
19. The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases.
Pathak JL; Bravenboer N; Klein-Nulend J
Front Endocrinol (Lausanne); 2020; 11():405. PubMed ID: 32733380
[TBL] [Abstract][Full Text] [Related]
20. Osteocyte regulation of bone mineral: a little give and take.
Atkins GJ; Findlay DM
Osteoporos Int; 2012 Aug; 23(8):2067-79. PubMed ID: 22302104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
